BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rothova, A.
Right arrow Articles by Treffers, W F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rothova, A.
Right arrow Articles by Treffers, W F.
Br J Ophthalmol 1998;82:1306-1308 ( November )

Azithromycin for ocular toxoplasmosis

Aniki Rothova, Lotje E H Bosch-Driessen, Ninette H van Loon, W Frits Treffers

Department of Ophthalmology, FC Donders Institute, Academic Hospital Utrecht, Netherlands

Correspondence to: Aniki Rothova, MD, F C Donders Institute, Department of Ophthalmology, Academic Hospital Utrecht, PO Box 85 500, 3508 GA Utrecht, Netherlands.

Accepted for publication 15 April 1998

AIMS---To investigate the efficacy of azithromycin in patients with ocular toxoplasmosis.
METHODS---11 immunocompetent patients with ocular toxoplasmosis were treated with azithromycin (500 mg the first day, followed by 250 mg/day for 5 weeks). Ocular and systemic examinations were performed during active retinitis episodes and all patients were followed for at least 1 year.
RESULTS---The intraocular inflammation disappeared within 4 weeks in seven patients, including two cases with progressive retinitis despite previous treatment with pyrimethamine, sulphadiazine, and folinic acid. Recurrence of retinitis occurred in three patients (27%) within the first year of follow up. No systemic side effects of azithromycin were encountered.
CONCLUSION---These results indicate that although azithromycin cannot prevent recurrent disease it may be an effective alternative for patients with ocular toxoplasmosis who cannot tolerate standard therapies.

Keywords: azithromycin; ocular toxoplasmosis

© 1998 by British Journal of Ophthalmology




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1998 by the BMJ Publishing Group Ltd.